Want to see CH:KURN full AI Analyst Report?

Kuros Biosciences (KURN) Price & Analysis

10 Followers

KURN Stock Chart & Stats

CHF28.16

-CHF0.35(-1.68%)

At close: Mar 06 4:00 PM EST

CHF28.16

-CHF0.35(-1.68%)

Day’s Range― - ―

52-Week RangeCHF17.69 - CHF34.20

Previous CloseN/A

Volume98.33K

Average Volume (3M)128.87K

Market Cap

CHF754.45M

Enterprise ValueCHF761.29M

Total Cash (Recent Filing)CHF15.66M

Total Debt (Recent Filing)CHF3.94M

Price to Earnings (P/E)446.0

Beta1.42

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.04

Shares Outstanding39,458,786

10 Day Avg. Volume110,510

30 Day Avg. Volume128,868

Financial Highlights & Ratios

PEG Ratio-3.21

Price to Book (P/B)15.78

Price to Sales (P/S)8.71

P/FCF Ratio-439.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF38.00

Price Target Upside34.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.31

Revenue Forecast (FY)CHF200.67M

Bulls Say, Bears Say

Bulls Say

Revenue ScalingSustained multiyear revenue scaling indicates durable commercial traction and increasing market penetration in orthobiologics. Larger recurring procedure-driven sales improve leverage on fixed costs, support broader distribution, and make future margin expansion and investment in R&D or sales more financially viable over 2–6 months and beyond.

Very High Gross MarginsAn ~86% gross margin profile implies structural product-level profitability and pricing power for the synthetic bone graft. High gross margins allow the company to absorb commercial and SG&A investments while preserving operating leverage, supporting sustainable operating margin improvement if revenue growth continues.

Conservative Balance SheetLow financial leverage provides flexibility to fund commercial expansion or absorb negative cash flow without excessive refinancing risk. A strong equity base reduces default risk, supports strategic investments or partnership opportunities, and lengthens the runway for converting improving earnings into sustained free cash flow.

Bears Say

Weak Cash GenerationNegative operating and free cash flow, despite accounting profits, signals working-capital or capex pressure and raises near-term funding sensitivity. If cash conversion does not recover, management may need external financing or slower reinvestment, constraining growth initiatives and increasing dilution or leverage risk over the medium term.

Thin Net ProfitabilityMargins have improved but remain slim, leaving limited buffer against pricing pressure, reimbursement changes, or slower procedure volumes. Small adverse swings in costs or revenues could erode profitability quickly, making long-term shareholder returns contingent on continued revenue expansion and tight cost control.

Concentration On Product Sales / MarketHeavy reliance on a single product category and concentrated geographic/clinical markets amplifies exposure to competitive alternatives, hospital purchasing decisions, and surgical adoption cycles. Limited diversification in revenue streams increases sensitivity to procedure volumes and payer or regulatory shifts, constraining resilience over time.

Kuros Biosciences News

Kuros Biosciences posts 51% Q1 sales surge on MagnetOs growth and manufacturing expansion

Kuros Biosciences ( ($CH:KURN) ) has issued an announcement. Kuros Biosciences reported a 51% year-on-year increase in total...

3M ago

Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion

Kuros Biosciences ( ($CH:KURN) ) just unveiled an update. Kuros Biosciences reported a 72% jump in 2025 medical...

4M ago

Kuros Biosciences’ MagnetOs Study: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Study Overview: Kuros Biosciences is conducting a...

8M ago

CSBTF

Kuros Biosciences’ Clinical Study on MagnetOs Flex Matrix: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Kuros Biosciences is conducting a phase IV...

8M ago

CSBTF

Kuros Biosciences Reports Strong Revenue Growth and Strategic Expansion

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences announced a 77% year-over-year increase...

9M ago

Kuros Biosciences Investigates Allegations Against Former Board Member

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences is addressing media inquiries regarding the resignation...

10M ago

Kuros Biosciences Announces Board of Directors Changes

Kuros Biosciences ( ($CH:KURN) ) has provided an announcement. Kuros Biosciences announced changes to its Board of Directors,...

10M ago

Kuros Biosciences Reports Strong Revenue Growth in 2025

Kuros Biosciences ( ($CSBTF) ) has released its Q2 earnings. Here is a breakdown of the information Kuros...

11M ago

Kuros Biosciences Achieves Record Growth and First Operating Profit in H1 2025

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences reported a 78% increase in total medical...

11M ago

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported an 82% year-over-year increase...

1y ago

KURN FAQ

What was Kuros Biosciences Ltd.’s price range in the past 12 months?

Kuros Biosciences Ltd. lowest stock price was CHF17.69 and its highest was CHF34.20 in the past 12 months.

What is Kuros Biosciences Ltd.’s market cap?

Kuros Biosciences Ltd.’s market cap is CHF754.45M.

When is Kuros Biosciences Ltd.’s upcoming earnings report date?

Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 38 days.

How were Kuros Biosciences Ltd.’s earnings last quarter?

Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported CHF0.093 earnings per share for the quarter, beating the consensus estimate of CHF0 by CHF0.093.

Is Kuros Biosciences Ltd. overvalued?

According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kuros Biosciences Ltd. pay dividends?

Kuros Biosciences Ltd. does not currently pay dividends.

What is Kuros Biosciences Ltd.’s EPS estimate?

Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kuros Biosciences Ltd. have?

Kuros Biosciences Ltd. has 39,458,786 shares outstanding.

What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?

Kuros Biosciences Ltd. reported an EPS of CHF0.093 in its last earnings report, beating expectations of CHF0. Following the earnings report the stock price went up 10.609%.

Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?

Currently, no hedge funds are holding shares in CH:KURN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kuros Biosciences Ltd.

Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.

Kuros Biosciences (KURN) Earnings & Revenues

Historic Earnings Reports

KURN Company Deck

KURN Earnings Call

Q4 2026

0:00 / 0:00

KURN Stock 12 Month Forecast

Average Price Target

CHF38.00

▲(34.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"CHF17","28":"CHF28","39":"CHF39","22.5":"CHF22.5","33.5":"CHF33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,22.5,28,33.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.44,19.944615384615386,21.44923076923077,22.953846153846154,24.45846153846154,25.963076923076922,27.46769230769231,28.972307692307695,30.47692307692308,31.981538461538463,33.48615384615385,34.99076923076923,36.495384615384616,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.44,19.944615384615386,21.44923076923077,22.953846153846154,24.45846153846154,25.963076923076922,27.46769230769231,28.972307692307695,30.47692307692308,31.981538461538463,33.48615384615385,34.99076923076923,36.495384615384616,{"y":38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.44,19.944615384615386,21.44923076923077,22.953846153846154,24.45846153846154,25.963076923076922,27.46769230769231,28.972307692307695,30.47692307692308,31.981538461538463,33.48615384615385,34.99076923076923,36.495384615384616,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.44,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >